<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572881</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0279</org_study_id>
    <nct_id>NCT03572881</nct_id>
  </id_info>
  <brief_title>Rhythmic Risk of Type 1 Brugada Syndrome and Pulmonary Infundibulum Mapping</brief_title>
  <acronym>SB-CARTO</acronym>
  <official_title>Assessment of Rhythmic Risk in Patients With Type 1 Brugada Syndrome by Pulmonary Infundibulum Mapping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brugada syndrome has been described as the association of a right bundle block with ST
      segment elevation on the V1 to V3 electrocardiogram in patients with a structurally normal
      heart. The rhythmic risk is thus difficult to evaluate in asymptomatic patients in whom the
      rate of events is estimated at 0.2 to 1.4% of events per year. In addition, the predictive
      value of ventricular pacing remains controversial; There is therefore currently no review to
      effectively assess rhythmic risk in patients with Brugada type I syndrome.

      Investigators aimed to show a difference in pulmonary infundibulum voltage mapping in
      symptomatic and asymptomatic patients with Brugada type 1 syndrome with a comparable ECG.

      The mapping of the pulmonary infundibulum will be performed during electrophysiological
      exploration. Only the catheter used differs from the usual procedure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of different voltage zones by endocardial mapping of the pulmonary infundibulum between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1</measure>
    <time_frame>Day 1</time_frame>
    <description>The voltage zone are defined with :
measurement of unipolar and bipolar local voltage (mV)
the scar surface
the surface of the bordering area
the surface of healthy tissue
the quantification of the number of fractionated potentials and density with respect to the size of the infundibulum and the scar (if present)
the analysis of the heterogeneity of the voltage (study of dispersion)
analysis of propagation card velocities in sinus rhythm and ventricular pacing (mm / s)
analysis of ventricular arrhythmia activation if positive ventricular pacing and good hemodynamic tolerance (focal / reentrant / reentrant macro).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brugada Syndrome Type 1</condition>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endocardial mapping</intervention_name>
    <description>An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.</description>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_label>Symptomatic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 21

          -  Brugada Type 1 syndrome

          -  Age : 50-60 years old

          -  Asymptomatic

          -  Signed informed consent

        Group2

          -  Brugada Type 1 syndrome

          -  Age &gt;18 years old

          -  Implantable defibrillator

          -  Having received at least 1 appropriate shock or a sudden sudden death

          -  Signed informed consent

        Groups 1 and 2

        Exclusion Criteria:

          -  Brugada Type 2 or 3 syndrome

          -  Contraindication to electrophysiological exploration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe CHEVALIER, MD PhD, Pr</last_name>
    <phone>4 72 35 70 27</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.morel@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie MOREL, CRA</last_name>
    <phone>4 72 35 73 81</phone>
    <phone_ext>+33</phone_ext>
    <email>elodie.morel01@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Chevalier, Pr</last_name>
      <phone>4 72 35 70 27</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.chevalier@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elodie Morel, CRA</last_name>
      <phone>4 72 35 73 81</phone>
      <phone_ext>+33</phone_ext>
      <email>elodie.morel01@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brugada syndrome</keyword>
  <keyword>ventricular arrhythmia</keyword>
  <keyword>sudden death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brugada Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

